Ann Oncol 29 (9): 1939-1947, 2018.[PUBMED Abstract] Barroso-Sousa R, Jain E, Cohen O, et al.: Prevalence and mutational determinants of high tumor mutation burden in breast cancer.
Ann Oncol 31 (3): 387-394, 2020.[PUBMED Abstract] Marabelle A, Fakih M, Lopez J, et al.: Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Lancet Oncol 21 (10): 1353-1365, 2020.[PUBMED Abstract] Alva AS, Mangat PK, Garrett-Mayer E, et al.: Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.